Nexus Pharmaceuticals
Daniel Imhoff is an accomplished analytical scientist with extensive experience in method development, particularly HPLC. Currently serving as Lead Analytical Scientist at Nexus Pharmaceuticals, Inc. since July 2019, Daniel has progressed through various roles including Analytical Scientist III. Prior experience includes positions at Adello Biologics, LLC as QC Analyst IV, and Celgene as Sr. Scientist, where Daniel authored and executed study protocols and reports. Earlier roles at Morton Grove Pharmaceutical, Dentsply Pharmaceutical, and Abbott showcased proficiency in HPLC assays, troubleshooting, and laboratory management. Daniel holds a Master of Science in Analytical Chemistry and a Certificate in Regulatory Science from the Illinois Institute of Technology, alongside bachelor's degrees in Forensic Chemistry and Biological Sciences from Ohio University.
Nexus Pharmaceuticals
Nexus Pharmaceuticals is a US-based, family-owned, minority-owned healthcare company and proud diverse supplier. We specialize in innovative processes to make difficult-to-manufacture specialty drugs that are easier to use, less labor-intensive, and more streamlined in practice. Nexus ensures that its high-quality, FDA-approved drugs fulfill a critical, unmet medical need and delivers dependable life-saving treatment options when and where they’re needed most. We are in the process of building Project Tomorrow – a state-of-the-art manufacturing facility in Pleasant Prairie, Wisconsin and only project of its kind in the last 30 years. Read about our commitment to Wisconsin and see our progress at nexuspharma.net/project-tomorrow